IL-2 has proven activity against cancer, having been sold as Proleukin (aldesleukin) for kidney and skin cancers since the early 1990s, originally by Chiron and latterly by Clinigen. It is known ...

Aldesleukin is under clinical development by Iltoo Pharma and currently in Phase II for Miscarriage. According to GlobalData, Phase II drugs for Miscarriage does not have sufficient historical data to ...

Aldesleukin is under clinical development by Iltoo Pharma and currently in Phase II for Bipolar Disorder (Manic Depression). According to GlobalData, Phase II drugs for Bipolar Disorder (Manic ...

Five patients with refractory SLE were treated daily with subcutaneous injections of 1.5 million IU of human IL-2 (aldesleukin) for five consecutive days, and PBMC were analysed by flow cytometry.

For homogeneity and proper cross-analyses, we report here the results of the first 46 patients who have been treated with IL-2 as Aldesleukin (Proleukin 18 MIU, Novartis Pharma SAS, Rueil-Malmaison, ...

Primary non-Hodgkin's lymphoma of the breast (PBNHL) is uncommon. There have been only a few reports of breast lymphoma in the radiology literature. In this case report, we describe mammographic ...

Non-Hodgkin's lymphoma invades the brain, the vitreous body and nerves of the eye, the meninges, and the nerve roots of brain and spine, leading to the development of a primary CNS lymphoma. The ...

Despite advances in the diagnostic and therapeutic modalities, the prognosis of several solid tumor malignancies remains poor. Different factors associated with solid tumors including a varied genetic ...